HOME >> MEDICINE >> NEWS
Acrux and Oreganon further expand their collaboration

Drug delivery company Acrux (ASX: ACR), announced today that it has signed a further agreement with Organon, the human healthcare business unit of Akzo Nobel, expanding the two parties' collaboration. This follows the recently announced deal under which Organon and Acrux will develop and commercialise contraceptives, delivered through the skin using Acrux's unique spray technology.

Under the new agreement, Organon has licensed Acrux's technology for delivery of a non-hormone, proprietary Organon drug, for a substantial global women's health market.

"The expansion of our important relationship with Organon, one of the leading innovators in women's health, confirms that our unique spray technology has even broader potential" said Acrux CEO Richard Treagus.

"This adds a new, non-hormone drug to our pipeline and demonstrates the potential to use the technology to deliver drugs owned by our partners", he added.

Organon executive vice president, Research and Development, David Nicholson commented "The Acrux technology is an appealing method of delivering medication, with the potential to extend the choices available for women to fit their needs and lifestyle."

Acrux will be responsible for developing formulations of the undisclosed compound and upon successful completion; Organon will undertake and fund all clinical trials, regulatory submissions, manufacturing and commercialization efforts.

Acrux may receive payments totalling US$12 million as development and regulatory milestones are achieved.

Acrux will also earn royalties on worldwide sales of the product.


'"/>

Contact: Richard Treagus
richard.treagus@acrux.com.au
61-383-790-100
Research Australia
6-Mar-2007


Page: 1

Related medicine news :

1. Acrux completes enrollment in key phase 2 trial
2. Acrux granted first grant in Europe, triggering payment from Lilly
3. Acrux patent portfolio advances in USA
4. Acrux acquires rights to commercialise worlds first contraceptive spray
5. Four new us patents granted to Acrux for transdermal drug delivery
6. Acrux reports progress in development of Testosterone MD-Lotion(R) for men
7. Stomach cancer rate set to fall further 25 percent over next decade
8. High tech help to prevent further heart disease
9. Altered activity in receptor pair points to further complexity in schizophrenia pathology
10. Mount Sinai and YAI/NIPD Network join forces to further quality of care for people with autism
11. Data further examines Seroquel (quetiapine fumarate) treatment for bipolar depression

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... Las Vegas, Nevada (PRWEB) , ... June 24, ... ... their Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and ... The Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
Breaking Medicine Technology:
Cached News: